Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sinovac Biotech Ltd.    SVA   AGP8696W1045

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Brazil health authority OKs import of 6 mln doses of Sinovac coronavirus vaccine

10/23/2020 | 04:34pm EST

RIO DE JANEIRO, Oct 23 (Reuters) - Brazil's health regulator Anvisa said in a statement on Friday it authorized Sao Paulo's Butantan Institute biomedical center to import 6 million doses of a coronavirus vaccine candidate developed by China's Sinovac .

The vaccine, known as CoronaVac, is still in phase 3 clinical trials in Brazil and has not been registered for wider use in Brazil, Anvisa said. (Reporting by Pedro Fonseca, writing by Jake Spring, editing by Chris Reese)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
EURO / BRAZILIAN REAL (EUR/BRL) -0.29% 6.2889 Delayed Quote.41.18%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
All news about SINOVAC BIOTECH LTD.
05:20pBrazil sees one-dose, unfrozen vaccine as ideal for COVID-19 -official
RE
11/30Q&A : Where are we in the COVID-19 vaccine race?
RE
11/27Philippines secures 2.6 mln doses of AstraZeneca's COVID-19 vaccine
RE
11/23Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - offi..
RE
11/23Sao Paulo expects regulator approval for Sinovac vaccine by January
RE
11/23Q&A : Where are we in the COVID-19 vaccine race?
RE
11/20SINOVAC BIOTECH : Pfizer eyes rapid COVID-19 vaccine roll-out in Latam after U.S..
RE
11/20Britain asks regulator to assess Pfizer vaccine for suitability
RE
11/20UK asks regulator to assess Pfizer vaccine for suitability
RE
11/20Sinovac may get Phase III trial results of COVID-19 vaccine by December, exec..
RE
More news
Financials (USD)
Sales 2019 246 M - -
Net income 2019 44,9 M - -
Net cash 2019 183 M - -
P/E ratio 2019 17,8x
Yield 2019 -
Capitalization 640 M 640 M -
EV / Sales 2018 1,38x
EV / Sales 2019 1,86x
Nbr of Employees 910
Free-Float 50,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang Chief Financial Officer & Vice President
Qiang Gao Vice President-Research & Development
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.-6.77%640
CSL LIMITED7.84%99 427
SAMSUNG BIOLOGICS CO.,LTD.81.52%46 940
BIOGEN INC.-19.06%36 958
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.151.53%30 386
ALEXION PHARMACEUTICALS, INC.14.50%26 723